BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Subscribe To Our Newsletter & Stay Updated